logo
Plus   Neg
Share
Email

Eli Lilly: Taltz Shows Efficacy In Phase 4 Study - Quick Facts

Eli Lilly and Company (LLY) said Taltz (ixekizumab), an IL-17A inhibitor, met the primary and all major secondary endpoints in the phase 4 IXORA-R study. The study involved 1,027 patients with moderate to severe plaque psoriasis. At 12 weeks, Taltz showed superiority in the proportion of patients achieving complete skin clearance compared to TREMFYA, a IL-23/p19 inhibitor. The safety data was consistent with prior results.

The company plans to submit detailed data from the study at scientific meetings and in peer-reviewed journals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Boy Scouts of America recalled about 78,000 units of Cub Scout outdoor activity pins for violating the federal lead content ban, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the activity pin's face and shaft contain levels of lead that exceed the federal lead content ban. Lead is toxic if ingested by young children and can cause adverse health issues. McDonald's Corp. is delaying the reopening of all dine-in services in its U.S. restaurants by 21 days due to the increase in coronavirus cases across the country, reports said citing an internal letter. The burger chain said, "Our resiliency will be tested again. COVID-19 cases are on the rise." The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..."
Follow RTT